SCHEMBL5067504

SCHEMBL5067504

CSc1ncnc2sc(C(N)=O)nc12

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
NOTUM Q6P988 7/20 0.38
DYRK1A Q13627 4/20 0.36
CSNK2A2 P19784 4/20 0.33
CSNK2B P67870 4/20 0.33
CSNK2A1 P68400 4/20 0.33
KMT2A Q03164 2/20 0.33
IKBKB O14920 1/20 0.33
LIMK1 P53667 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
EIF4E P06730 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
HTT P42858 1/20 0.32
DYRK1B Q9Y463 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5458654 0.86 ALDH1A1 (0.41) ALDH1A1LMNANOTUMCSNK2A2CSNK2B
SCHEMBL16012996 0.82 MKNK1 (0.46) ALDH1A1LMNANOTUMCSNK2A2CSNK2B
SCHEMBL5464890 0.82 ALDH1A1 (0.42) ALDH1A1LMNANOTUMDYRK1ATDP1
SCHEMBL5065405 0.79 HSD17B10 (0.44) ALDH1A1LMNANOTUMCSNK2A2CSNK2B
SCHEMBL16371583 0.78 DYRK1A (0.33) DYRK1AIKBKBLIMK1EIF4EMKNK1
SCHEMBL16013396 0.77 MKNK1 (0.48) ALDH1A1LMNANOTUMKMT2AMKNK1
SCHEMBL5068984 0.77 MKNK2 (0.42) ALDH1A1LMNAIKBKBLIMK1EIF4E
SCHEMBL24401465 0.75 NOTUM (0.43) ALDH1A1LMNANOTUMKMT2AMKNK1
SCHEMBL16013302 0.75 MKNK1 (0.52) ALDH1A1LMNANOTUMMKNK1
SCHEMBL5064699 0.74 MKNK1 (0.40) ALDH1A1NOTUMKMT2AMKNK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108495855-B Fused thiazolopyrimidine derivatives as MNK inhibitors 生命弧度公司 2022-05-31 CN disclosed
EP-3019505-A1 SUBSTITUTED PYRAZOLO-PYRIDINAMINES Bayer Pharma Aktiengesellschaft (DE) 2016-05-18 EP disclosed
WO-2015004024-A1 SUBSTITUTED PYRAZOLO-PYRIDINAMINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-01-15 WO disclosed
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
EP-1731523-A1 THIAZOLOPYRIMIDINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2006-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269238-A1 Thiazolopyrimidine Derivative FGFR3, FGFR1, ERBB3 ALDH1A1 1911/4885LMNA 4401/4885NOTUM 4612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.